Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|February 23, 2021
3 Ways to Turn Client Experience into Your Competitive Advantage
Author(s)Sikich
*** Thursday, March 11, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET *** How can CROs continue to grow in today’s increasingly competitive market? Learn how you can turn client experience into your competitive advantage. *** On demand available after final airing until Mar. 11, 2022 ***
Register free:
Event Overview:
How can CROs continue to grow and secure repeat business in today's increasingly competitive market? The need to improve customer retention and satisfaction has become more important than ever in providing stable streams of revenue. In this brief, 30–minute webcast, discover how you can turn client experience into your competitive advantage. Industry experts Chris Manchester and Matt Mountain will demonstrate how you can understand your clients better, take the right steps to move projects along, and make sure that all activities and processes you have in place keep your clients coming back for more; all by leveraging technology solutions you may already have in place.
Key Learning Objectives:
- Give your clients access to the information they need
- Streamline pricing and quoting processes for you and your clients
- Arm your Study/Project Managers with the information they need to deliver superior customer service that keep your clients coming back time and time again
Speakers: Christopher Manchester, NetSuite Managing Consultant, Sikich
Matt Mountain, Salesforce Partner, Sikich
Sponsor: Sikich
Time and Date: Thursday, March 11, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET
On demand available after final airing until Mar. 11, 2022
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5